TACE Treats Nodular Goiter

Transarterial Chemoembolization With Bleomycin: A Promising Treatment of Giant Nodular Goiter

Status

Enrolling by invitation

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07258199

Enrollment

Registered

2025-12-02

Start date

2025-09-01

Completion date

2027-09-01

Last updated

2025-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nodular Goiter

Keywords

Transarterial chemoembolization, Giant nodular goiter, Bleomycin, Drug-loaded microspheres

Brief summary

transarterial bleomycin chemoembolization represents a novel minimally invasive therapeutic approach for the management of giant nodular goiter.

Interventions

PROCEDURETACE

TACE, 15,000U bleomycin and 200-400μm drug-loaded microspheres

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Clinical criteria: thyroid enlargement, mostly painless, with compressive symptoms (such as dysphagia, dyspnea) being less common; thyroid function is mostly normal, and a small number may be accompanied by hyperthyroidism or hypothyroidism. * Imaging examinations: ultrasound shows multiple solid or cystic-solid nodules with clear boundaries and no malignant signs such as microcalcification and a vertical-to-horizontal diameter ratio \>1. * Pathological criteria: follicular epithelial cell hyperplasia, no nuclear atypia, and no malignant cellular characteristics (such as mitotic figures, infiltrative growth, etc.). In this study, a thyroid goiter with at least one diameter exceeding 4 cm was considered a giant goiter

Exclusion criteria

* abnormal coagulation profiles; * hepatic or renal impairment; * allergy to contrast media; * refusal of interventional therapy and requirement for surgical treatment or other therapies

Design outcomes

Primary

Measure	Time frame	Description
volume	1-, 3-, 6-, 12-month follow up	Lesion volume measurement on contrast-enhanced CT

Secondary

Measure	Time frame	Description
longest diameter	1-, 3-, 6-, 12-month follow-up	Measurement of the longest lesion diameter on contrast-enhanced CT
lesion shrinkage	1-, 3-, 6-, 12-month follow-up	—

Other

Measure	Time frame
postoperative complications	1-, 3-, 6-, 12-month follow-up

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026